Solid Tumors

Here you'll find selected publications pertaining to the blood-based enumeration of immune cells in the respective disease indication

• General
• • Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies (Hernandez, 2020)

• CCR6+ cells
• • The CCL20-CCR6 Axis in Cancer Progression (Kadamoto, 2020)

• Myeloid-derived suppressor cells (MDSC)
• • Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells (Apodaca, 2019)
  • Myeloid-derived suppressor cells coming of age (Review) (Veglia, 2018)
  • Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma (Flörcken, 2015)

• PD-1+ cells
• • Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab (Pluim, 2019)
  • Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer (Zheng, 2016)

• Th17/Treg Balance
• • When worlds collide: Th17 and Treg cells in cancer and autoimmunity (Knochelmann, 2018)

• Treg
• • The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns (Türbachova, 2013)